Skip to main content
Evidence Snapshot

BDNF/NT-3 growth factors receptor

CHEMBL4898 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4898
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats BDNF/NT-3 growth factors receptor as ChEMBL target CHEMBL4898, mapped to UniProt Q16620. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
BDNF/NT-3 growth factors receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4898
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16620
BDNF/NT-3 growth factors receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why BDNF/NT-3 growth factors receptor matters

As of 2026-09-13

BDNF/NT-3 growth factors receptor is reviewed as BDNF/NT-3 growth factors receptor (UniProt Q16620); BDNF/NT-3 growth factors receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 22 approved drugs, 2630 compounds, and 535 assays, with lead potency reaching pChEMBL 10.3.

Disease context
cancer

BDNF/NT-3 growth factors receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include REPOTRECTINIB.

Start review with cancer because it currently carries approved-linked support. Linked drugs include REPOTRECTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 22 approved drugs, 2630 compounds, and 535 assays for this target. The dominant activity type is KI. CHEMBL4298138 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL4298138 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
22 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why BDNF/NT-3 growth factors receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q16620, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2630
Total Compounds
535
Total Assays
22
Approved Drugs
IC50: 912.0, KI: 957.0, EC50: 24.0, KD: 141.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4298138
 10.3 IC50 Approved
No preferred name
CHEMBL388978
 10.2 IC50 —
No preferred name
CHEMBL3673452
 10.0 IC50 Clinical
No preferred name
CHEMBL6044141
 9.7 Kd —
No preferred name
CHEMBL3678285
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
REPOTRECTINIB
CHEMBL4298138
 2023
QUIZARTINIB
CHEMBL576982
 2023
ENTRECTINIB
CHEMBL1983268
 2019
LAROTRECTINIB
CHEMBL3889654
 2018
LAROTRECTINIB SULFATE
CHEMBL3989939
 2018
LORLATINIB
CHEMBL3286830
 2018
MIDOSTAURIN
CHEMBL608533
 2017
NINTEDANIB
CHEMBL502835
 2014
BOSUTINIB
CHEMBL288441
 2012
CRIZOTINIB
CHEMBL601719
 2011
RUXOLITINIB
CHEMBL1789941
 2011
NILOTINIB
CHEMBL255863
 2007
SUNITINIB
CHEMBL535
 2006
SORAFENIB
CHEMBL1336
 2005
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4898